INSILICO (03696) announced that the Group has entered into a multi-year research and development collaboration with Servier, a globally independent pharmaceutical company managed by a foundation. The collaboration, valued at up to $888 million, will leverage the Group's proprietary AI platform, Pharma.AI, to focus on challenging targets in the oncology field, aiming to identify and develop novel therapeutic drugs. Under the agreement, the Group is eligible to receive up to $32 million in an upfront payment and near-term R&D milestone payments, and will lead the application of its AI technology platform to discover and develop potential candidate drugs meeting predefined criteria, while Servier will co-share R&D costs and lead subsequent clinical validation and commercialization processes. Christophe Thurieau, Executive Director of Servier Research, stated, "This collaboration underscores Servier's commitment to leveraging cutting-edge technologies to address unmet medical needs and ultimately benefit patients, and also reflects our confidence in INSILICO's proprietary and validated AI platform." Dr. Alex Zhavoronkov, Founder, CEO, and Chief Business Officer of INSILICO, expressed, "I am tremendously excited about this partnership, which signifies that our AI-powered drug discovery capabilities and strength have once again gained recognition. As we integrate generative AI more deeply into every stage of the drug R&D value chain, I believe the future of pharmaceutical super-intelligence is near, where AI agents can truly make decisions and design experiments, creating a virtuous cycle that drives drug development to be faster, smarter, and safer."
Comments